A032101: A PHASE 2 TRIAL OF ADT INTERRUPTION IN PATIENTS RESPONDING EXCEPTIONALLY TO AR-PATHWAY INHIBITOR IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): A-DREAM
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
Rocky Mountain Regional VA Medical Center
Principal Investigator
![Photograph of Jessica McDermott](https://som.ucdenver.edu/FIMS/Content/faculty/23848/CU-Doctors-23848.jpg)
Jessica McDermott
Study ID
Protocol Number: 22-1383
More information available at ClinicalTrials.gov: NCT05241860
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers